Physician profile
Max Schlesinger
NPI 1093100786
$2,520.18
in general payments reported to CMS, 2019-2025
14 companies · $445 in 2025
The $445 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $121 · 2021: $651 · 2022: $146 · 2023: $399 · 2024: $758 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,453 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,452.57 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $345.48 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $317.12 | 2022-2025 | Eylea Hd |
| Bausch & Lomb Americas INC. | $266.61 | 2024 | Envista Mx60 Iol, Xipere |
| Abbvie INC. | $263.86 | 2024-2025 | |
| Astellas Pharma US INC | $216.89 | 2024-2025 | Izervay |
| Genentech USA, INC. | $171.08 | 2023-2025 | Vabysmo |
| Allergan, INC. | $159.05 | 2021 | |
| Alcon Vision LLC | $152.10 | 2022-2023 | Rhopressa, Rocklatan, Simbrinza |
| Cardinal Health 110 LLC | $150.00 | 2024 | |
| Alimera Sciences, INC. | $142.18 | 2021 | |
| Eyepoint US, INC. | $125.00 | 2021 | |
| Horizon Therapeutics Plc | $124.99 | 2023 | Tepezza |
| Amgen INC. | $55.98 | 2025 | Tepezza |
| Ani Pharmaceuticals, INC. | $29.84 | 2025 | Iluvien |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Schlesinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.